What are the limitations of the hct ci?

While the hct ci is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the hct ci to ensure safe bedside use and optimal diagnostic accuracy.

How does the hct ci compare to other hematology scores?

The hct ci is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the hct ci free to use?

Yes. OpiCalc provides the hct ci completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

HCT-CI (Comorbidity Index)

HCT-CI (Sorror Score): Assesses pre-transplant comorbidity burden. Scores correlate with Non-Relapse Mortality (NRM).

HCT-CI Calculation

0

Low Risk (NRM ~14%)

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Pre-transplant assessment of non-relapse mortality (NRM) risk in patients undergoing allogeneic or autologous HSCT.

Identifying specific comorbidities that may require optimized management before conditioning.

Differentiating patients into low, intermediate, and high-risk groups for transplant toxicity.

Patient Population

Adult and pediatric patients scheduled for HSCT. Validated across varied conditioning intensities and donor sources.

The "Sorror Score"

Often referred to as the Sorror Score (after Dr. Mohamed Sorror), it significantly outperforms the Charlson Comorbidity Index (CCI) in the transplant setting.

Section 2

Formula & Logic

High Weight Comorbidities (3 pts)

Moderate/severe liver disease (Cirrhosis, Bilirubin > 2x ULN, AST/ALT > 5x ULN).

Prior solid organ malignancy (except non-melanoma skin cancer).

Moderate Weight Comorbidities (2 pts)

Cardiac (EF ≤ 50% or severe arrhythmia).

Infection (Active systemic infection at time of conditioning).

Moderate/severe pulmonary (DLCO or FEV1 ≤ 65%).

Cerebrovascular disease.

Low Weight Comorbidities (1 pt)

Arrhythmia (AF/A-flutter/SVT).

Bilirubin > ULN but ≤ 2x.

Diabetes (Requiring therapy).

Inflammatory Bowel Disease.

Mild Pulmonary (DLCO or FEV1 66-80%).

Peptic Ulcer (History of).

Renal (Cr > 2.0 mg/dL or Dialysis).

Rheumatologic.

Section 3

Pearls/Pitfalls

Risk Stratification

HCT-CI Score	Risk Group	2-year NRM
0	Low	~14%
1 - 2	Intermediate	~21%
≥ 3	High	~41%

The Liver & Lung Dominance

Liver and pulmonary dysfunction account for the majority of the score's predictive power. Patients with combined severe pulmonary and liver disease have extremely high NRM.

Section 4

Evidence Appraisal

Primary Score

Hematopoietic cell transplantation-specific comorbidity index: a new tool for risk assessment before allogeneic transplantation.

Sorror ML et al. • Blood. 2005;106(8):2912-9. n=1,055 patients.

View Source

Validation of a hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in a large multi-institutional cohort.

Sorror ML et al. • Blood. 2007;110(5):1618-20.

View Source

Section 5

Literature

Development

Developed by Dr. Mohamed Sorror at the Fred Hutchinson Cancer Research Center. It was designed to address the fact that age alone is a poor surrogate for transplant fitness.

Last Comprehensive Review: 2026

Related Hematology Tools

Revised Response Criteria

PCNSL MSKCC Score

ISS

R-ISS

IMWG Response Criteria

MRD Assessment Threshold Interpreter

mSMART 3.0

SLiM-CRAB Criteria

Durie-Salmon Staging

AL Amyloidosis Staging

Have feedback about this calculator?Let us know.

HCT-CI (Comorbidity Index)

HCT-CI (Sorror Score): Assesses pre-transplant comorbidity burden. Scores correlate with Non-Relapse Mortality (NRM).

HCT-CI Calculation

0

Low Risk (NRM ~14%)

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Pre-transplant assessment of non-relapse mortality (NRM) risk in patients undergoing allogeneic or autologous HSCT.

Identifying specific comorbidities that may require optimized management before conditioning.

Differentiating patients into low, intermediate, and high-risk groups for transplant toxicity.

Patient Population

Adult and pediatric patients scheduled for HSCT. Validated across varied conditioning intensities and donor sources.

The "Sorror Score"

Often referred to as the Sorror Score (after Dr. Mohamed Sorror), it significantly outperforms the Charlson Comorbidity Index (CCI) in the transplant setting.

Section 2

Formula & Logic

High Weight Comorbidities (3 pts)

Moderate/severe liver disease (Cirrhosis, Bilirubin > 2x ULN, AST/ALT > 5x ULN).

Prior solid organ malignancy (except non-melanoma skin cancer).

Moderate Weight Comorbidities (2 pts)

Cardiac (EF ≤ 50% or severe arrhythmia).

Infection (Active systemic infection at time of conditioning).

Moderate/severe pulmonary (DLCO or FEV1 ≤ 65%).

Cerebrovascular disease.

Low Weight Comorbidities (1 pt)

Arrhythmia (AF/A-flutter/SVT).

Bilirubin > ULN but ≤ 2x.

Diabetes (Requiring therapy).

Inflammatory Bowel Disease.

Mild Pulmonary (DLCO or FEV1 66-80%).

Peptic Ulcer (History of).

Renal (Cr > 2.0 mg/dL or Dialysis).

Rheumatologic.

Section 3

Pearls/Pitfalls

Risk Stratification

HCT-CI Score	Risk Group	2-year NRM
0	Low	~14%
1 - 2	Intermediate	~21%
≥ 3	High	~41%

The Liver & Lung Dominance

Liver and pulmonary dysfunction account for the majority of the score's predictive power. Patients with combined severe pulmonary and liver disease have extremely high NRM.

Section 4

Evidence Appraisal

Primary Score

Hematopoietic cell transplantation-specific comorbidity index: a new tool for risk assessment before allogeneic transplantation.

Sorror ML et al. • Blood. 2005;106(8):2912-9. n=1,055 patients.

View Source

Validation of a hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in a large multi-institutional cohort.

Sorror ML et al. • Blood. 2007;110(5):1618-20.

View Source

Section 5

Literature

Development

Developed by Dr. Mohamed Sorror at the Fred Hutchinson Cancer Research Center. It was designed to address the fact that age alone is a poor surrogate for transplant fitness.

Last Comprehensive Review: 2026

Related Hematology Tools

Revised Response Criteria

PCNSL MSKCC Score

ISS

R-ISS

IMWG Response Criteria

MRD Assessment Threshold Interpreter

mSMART 3.0

SLiM-CRAB Criteria

Durie-Salmon Staging

AL Amyloidosis Staging

Have feedback about this calculator?Let us know.